Halozyme Taps Veteran CFO David Ramsay as Interim Leader Amid Permanent Search

Event summary

  • David Ramsay appointed Interim CFO of Halozyme, effective March 23, 2026.
  • Ramsay previously served as Halozyme's CFO from 2003–2009 and 2013–2015.
  • Company engaged a leading executive search firm to find a permanent CFO.
  • Ramsay brings 30+ years of financial leadership in biotech and life sciences.
  • Halozyme's ENHANZE® technology has touched over 1 million patient lives.

The big picture

Halozyme's appointment of David Ramsay as interim CFO underscores the company's focus on maintaining financial stability during the search for a permanent leader. Ramsay's extensive experience in scaling biotech companies aligns with Halozyme's strategic priorities, particularly as it expands its drug delivery technology portfolio. The move comes amid a competitive landscape where partnerships with major pharma players like Roche and Pfizer are critical for growth.

What we're watching

Leadership Stability
How quickly Halozyme can secure a permanent CFO and whether Ramsay's interim role impacts strategic decision-making.
Financial Strategy
Whether Ramsay's return will influence capital markets strategies or investor relations dynamics.
Technology Expansion
The pace at which Halozyme advances its Hypercon™ and Surf Bio technologies amid leadership transitions.